ORIC Pharmaceuticals, Inc. (ORIC)
NASDAQ: ORIC · IEX Real-Time Price · USD
+0.28 (3.15%)
At close: May 22, 2024, 4:00 PM
-0.17 (-1.85%)
After-hours: May 22, 2024, 6:35 PM EDT

Company Description

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States.

Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.

The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers.

It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals logo
Country United States
Founded 2014
IPO Date Apr 24, 2020
Industry Biotechnology
Sector Healthcare
Employees 102
CEO Dr. Jacob M. Chacko M.B.A., M.D.

Contact Details

240 E. Grand Ave., 2nd Floor
South San Francisco, California 94080
United States
Phone (650) 388-5600
Website oricpharma.com

Stock Details

Ticker Symbol ORIC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001796280
CUSIP Number 68622P109
ISIN Number US68622P1093
Employer ID 47-1787157
SIC Code 2834

Key Executives

Name Position
Dr. Richard A. Heyman Ph.D. Co-Founder, Independent Chairman and Member of Scientific Advisory Board
Dr. Jacob M. Chacko M.B.A., M.D. President, Chief Executive Officer and Director
Dominic G. Piscitelli CPA, M.B.A. Chief Financial Officer
Dr. Pratik S. Multani M.D., M.S. Chief Medical Officer
Dr. Charles L. Sawyers B.A., M.D., Ph.D. Co-Founder and Member of Scientific Advisory Board
Dr. Scott W. Lowe Ph.D. Co-Founder and Member of Scientific Advisory Board
Dr. Lori Sickels Friedman Ph.D. Chief Scientific Officer
Dr. Christian V. Kuhlen Esq., J.D., M.D. General Counsel
Daniel Iazzetti Vice President and Head of People
Dr. Edna Chow Maneval Senior Vice President of Clinical Development

Latest SEC Filings

Date Type Title
May 6, 2024 10-Q Quarterly Report
May 6, 2024 8-K Current Report
Apr 24, 2024 ARS Filing
Apr 24, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 24, 2024 DEF 14A Other definitive proxy statements
Mar 29, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 29, 2024 8-K Current Report
Mar 11, 2024 S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
Mar 11, 2024 10-K Annual Report
Mar 11, 2024 8-K Current Report